There are currently 664 clinical trials in Milwaukee, Wisconsin looking for participants to engage in research studies. Trials are conducted at various facilities, including Medical College of Wisconsin, Childrens Hospital of Wisconsin, Aurora Saint Luke's Medical Center and Aurora Sinai Medical Center. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
REdo tranScatheter Aortic Valve Replacement for Transcatheter aOrtic Valve failuRE
NCT06777368
Recruiting
The purpose of this study is to generate clinical evidence on valve safety and performance in subjects treated by redo Transcatheter Aortic Valve Replacement (TAVR).
Gender:
ALL
Ages:
Between 18 years and 105 years
Trial Updated:
05/30/2025
Locations: Aurora St. Lukes Medical Center, Milwaukee, Wisconsin
Conditions: Aortic Stenosis
Register for Updates
A Study to Evaluate the Efficacy, Safety, Pharmacokinetics (PK), and Pharmacodynamics (PD) of Satralizumab in Participants With Anti-N-methyl-D-aspartic Acid Receptor (NMDAR) or Anti-leucine-rich Glioma-inactivated 1 (LGI1) Encephalitis
NCT05503264
Recruiting
The purpose of this study is to assess the efficacy, safety, PK, and PD of satralizumab in participants with NMDAR and LGI1 encephalitis.
Gender:
ALL
Ages:
12 years and above
Trial Updated:
05/30/2025
Locations: Medical College of Wisconsin, Milwaukee, Wisconsin
Conditions: NMDAR Autoimmune Encephalitis, LGI1 Autoimmune Encephalitis
Register for Updates
A Study of LY4050784 in Participants With Advanced or Metastatic Solid Tumors
NCT06561685
Recruiting
The main purpose of this study is to find out whether the study drug, LY4050784, is safe, tolerable and effective in participants alone or in combination with other anticancer agents. In addition, with locally advanced or metastatic solid tumors with a BRG1 (Brahma-related gene 1, also known as SMARCA4) alteration who have previously received, do not qualify for, or are refusing standard of care treatments, or there is no standard therapy available for the disease. The study is conducted in two... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/29/2025
Locations: Medical College of Wisconsin, Milwaukee, Wisconsin
Conditions: Metastatic Solid Tumor, Advanced Solid Tumor, Non-small Cell Lung Cancer, SMARCA4-Deficient Tumor
Register for Updates
Testing the Use of the Combination of Selumetinib and Olaparib or Selumetinib Alone Targeted Treatment for RAS Pathway Mutant Recurrent or Persistent Ovarian and Endometrial Cancers, A ComboMATCH Treatment Trial
NCT05554328
Recruiting
This phase II ComboMATCH treatment trial compares selumetinib plus olaparib to selumetinib alone in women with endometrial or ovarian (fallopian tube and primary peritoneal) cancer that has come back (recurrent) or that remains despite treatment (persistent) and harbors a mutation in the RAS pathway. Selumetinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Olaparib is an inhibitor of PARP, an enzyme that helps repair deoxyribonucleic acid (DNA) when... Read More
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
05/29/2025
Locations: Aurora Cancer Care-Milwaukee, Milwaukee, Wisconsin +2 locations
Conditions: Recurrent Endometrial Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Fallopian Tube Carcinoma, Recurrent Primary Peritoneal Carcinoma
Register for Updates
BradycArdia paCemaKer With AV Interval Modulation for Blood prEssure treAtmenT
NCT06059638
Recruiting
A prospective, multinational, randomized, double-blind, clinical trial evaluating the safety and effectiveness of a novel atrioventricular interval modulation (AVIM) algorithm downloaded into a dual-chamber Medtronic Astra/Azure pacemaker.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/29/2025
Locations: Advocate Aurora Research Institute, LLC, Milwaukee, Wisconsin
Conditions: Hypertension, Hypertension, Systolic, Hypertension, Essential
Register for Updates
A Study Evaluating the Real World Experience of Participants Treated With BRIUMVI® (Ublituximab-xiiy) for Relapsing Multiple Sclerosis (RMS)
NCT06433752
Recruiting
The purpose of this study is to evaluate safety, effiectiveness, and to gain insight into the treatment experience of participants prescribed BRIUMVI® (ublituximab-xiiy) in the real-world setting
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/29/2025
Locations: TG Therapeutics Investigational Trial Site, Milwaukee, Wisconsin
Conditions: Relapsing Multiple Sclerosis, Multiple Sclerosis
Register for Updates
Study to Evaluate Safety, Efficacy and Pharmacokinetics (PK) of a Modified Regimen of Ublituximab
NCT05877963
Recruiting
The primary purpose of this phase 3b study is to assess the efficacy of a modified regimen of ublituximab as measured by T1 Gadolinium (Gd)-enhancing lesions and pharmacokinetics in participants with Relapsing Multiple Sclerosis (RMS). The study consists of 2 parts: Part A is single-armed and open-label and Part B is randomized, double-blind, placebo-controlled.
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
05/29/2025
Locations: TG Therapeutics Investigational Trial Site, Milwaukee, Wisconsin
Conditions: Relapsing Multiple Sclerosis
Register for Updates
A Study of Eltrekibart (LY3041658) in Adult Participants With Moderate to Severe Hidradenitis Suppurativa
NCT06046729
Recruiting
This study aims to find the appropriately safe and effective dose and dosing frequency for eltrekibart in adults with moderate-to-severe hidradenitis suppurativa (HS) for further clinical development. The study will last approximately 62 weeks and may include up to 31 visits.
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
05/29/2025
Locations: Medical College of Wisconsin, Milwaukee, Wisconsin
Conditions: Hidradenitis Suppurativa
Register for Updates
Efficacy/Safety of ALTB-268 in Subjects w/Moderately to Severely Active UC Refractory to Biologics
NCT06109441
Recruiting
ALTB-268-201 is a Phase 2a, multicenter, single arm, multiple-dose, open-label study evaluating the efficacy and safety of ALTB-268 in subjects with moderately to severely active UC. The study consists of a Screening Phase, an Induction Phase, a Maintenance Phase, and an OLE.
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
05/28/2025
Locations: Wisconsin Center for Advanced Research, Milwaukee, Wisconsin
Conditions: Ulcerative Colitis
Register for Updates
Tumor-agnostic Precision Immuno-oncology and Somatic Targeting Rational for You (TAPISTRY) Platform Study
NCT04589845
Recruiting
TAPISTRY is a Phase II, global, multicenter, open-label, multi-cohort study designed to evaluate the safety and efficacy of targeted therapies or immunotherapy as single agents or in rational, specified combinations in participants with unresectable, locally advanced or metastatic solid tumors determined to harbor specific oncogenic genomic alterations or who are tumor mutational burden (TMB)-high as identified by a validated next-generation sequencing (NGS) assay. Participants with solid tumors... Read More
Gender:
ALL
Ages:
All
Trial Updated:
05/28/2025
Locations: Froedtert and The Medical College of Wisconsin, Milwaukee, Wisconsin
Conditions: Solid Tumors
Register for Updates
A Platform Study of Novel Immunotherapy Combinations as First-Line Treatment in Participants With PD-L1 Positive Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck- GALAXIES H&N-202
NCT06062420
Recruiting
The primary purpose of the study is to evaluate the antitumor activity and safety of novel immunotherapy combinations compared with dostarlimab in participants with Programmed death ligand 1 (PD-L1) positive Recurrent/Metastatic (R/M) Head and Neck Squamous Cell Carcinoma (HNSCC).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/28/2025
Locations: GSK Investigational Site, Milwaukee, Wisconsin
Conditions: Neoplasms, Head and Neck
Register for Updates
MILD® Percutaneous Image-Guided Lumbar Decompression: A Medicare Claims Study
NCT03072927
Recruiting
This prospective longitudinal study will compare incidence rates of Medicare beneficiary surgical and minimally invasive intervention post index procedure, as well as harms associated with the MILD procedure, at 24 months post-treatment with MILD, tested against a control group of similar patients that have had a comparable procedure. This study will start with patients treated with a study procedure having an index date on or after January 1, 2017, and enrollment will continue until stopped by... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/28/2025
Locations: Aurora St Lukes Med Ctr, Milwaukee, Wisconsin +2 locations
Conditions: Lumbar Spinal Stenosis
Register for Updates